| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8924747 | Mayo Clinic Proceedings: Innovations, Quality & Outcomes | 2018 | 9 Pages |
Abstract
Disease control was excellent for patients who received SBRT for early-stage NSCLC, and this series represents the largest single-institution experience from the United States on SBRT for early-stage inoperable NSCLC. Higher pretreatment FDG-PET SUVmax was associated with increased risk of any recurrence, and the 50 Gy in 5 fractions dose prescription was associated with increased risk of local recurrence.
Keywords
FDG-PETRTOGSUVmaxSBRTITVDFSEBUSBEDdisease-free survivaloverall survivalcomputed tomographyPositron emission tomographyinternal target volumemaximum standardized uptake valueBiologically effective doseStereotactic body radiotherapyNon–small cell lung cancerNSCLCendobronchial ultrasonographyhazard ratioPETLocal controlRadiation Therapy Oncology Group
Related Topics
Health Sciences
Medicine and Dentistry
Critical Care and Intensive Care Medicine
Authors
Corey J. MD, Stephen J. MD, Nitesh N. MD, Joseph M. MD, Kenneth R. MD, Yolanda I. MD, Sean S. MD, MS, PhD, Christopher L. MD, Steven E. MD, Sujay A. MD, Jonathan B. MD, PhD, William G. MD, Johnny R. BS, Michael G. MS, Nancy N. MBA, Robert C. MD,
